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Edited by Patrick Aloy and Robert RussellAbstract To more eﬀectively target complex diseases like can-
cer, diabetes and schizophrenia, we may need to rethink our
strategies for drug development and the selection of molecular
targets for pharmacological treatments. Here, we discuss the po-
tential use of protein signaling networks as the targets for new
therapeutic intervention. We argue that by targeting the archi-
tecture of aberrant signaling networks associated with cancer
and other diseases new therapeutic strategies can be imple-
mented. Transforming medicine into a network driven endeavour
will require quantitative measurements of cell signaling pro-
cesses; we will describe how this may be performed and combined
with new algorithms to predict the trajectories taken by a cellular
system either in time or through disease states. We term this ap-
proach, network medicine.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Network biology1. The need for a novel drug development strategy
Drug discovery and development have resulted in many suc-
cessful therapies over the last century. Current drug develop-
ment eﬀorts almost uniformly focus on a speciﬁc step in a
well-described disease pathway and aim to identify highly spe-
ciﬁc inhibitors for this particular step. However, these strategies
have generally been less eﬀective for identifying therapeutically
useful approaches for treating complex diseases. This is sup-
ported by recent discouraging trends in the areas of complex
regulatory diseases including cancer and diabetes. Firstly, the
number of submissions for FDA approval declined in the
2000s, and this was coupled with a decline in all phases of drug
development. The average price of bringing a drug to market is
now approximately 860M USD [1], and there is a general trend
towards a rise in expenditure for drug development [2]. Sec-
ondly, only 25% of new drugs over the last decade were consid-
ered innovative, in the sense of a new drug indicated for a
previously unmet medical need [3], although this number is
likely to increase due to an increasing number of ﬁrst-in class
products [5]. Thirdly, although there was a net rise in small-Corresponding author.
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apeutics approved in the US from 1980 to 2001 this trend has
not continued from 1996 to 2002 [4], which indicates a more re-
cent slowdown in the success of drug discovery eﬀorts.
There are other important trends, for example, whereas most
current drugs were discovered before their molecular targets
were known, a recent trend towards more rational drug design
has been observed [8]. Increasingly more drugs are developed
in highly specialised biotech companies [6]. Furthermore, it
has been suggested that the increase in drug development price
is not due to an increase in clinical trial time, as the review pro-
cess time has actually declined [7]. It has been argued that the
current approval and funding systems favour non-risky drug
development towards well-studied targets [1]. This trend was
also observed in a recent network analysis that found that
an overabundance of follow-on drugs, that is to say, drugs
against already targeted proteins are over-represented in cur-
rent drug discovery eﬀorts [8].
Recently, more attention has been directed towards molecu-
lar drug targets in cellular signalling networks, such as protein
kinases and GPCRs. Therefore tools are needed to dig deeper
in protein networks associated with diseases and it will become
increasingly important to address issues such as sensitivity and
quantiﬁcation to focus more research on these frequently low-
er-abundance proteins.
Thus it seems that there are fewer drugs being developed and
that creating such compounds is increasingly diﬃcult and
expensive. Many papers have been written to discuss the pos-
sible economical and political reasons for this, some of which
are mentioned above; however few papers [17,19,24,25] have
addressed the limitations in the current strategy for selecting
drug targets of complex diseases such as cancer, diabetes and
mental illness.
Here, we will discuss the possibility that the hunt for a single
highly speciﬁc compound that targets a single molecular cellu-
lar target in many cases will likely fail for complex diseases.
Instead we propose that the molecular networks associated
with disease and in particular their dynamics as a target for
intervention. Thus, we suggest that protein signaling networks
are powerful drug targets. Here, we will discuss how quantita-
tive and directional protein interaction networks can be mon-
itored with current proteomics methods, and in combination
with recent advances in computational algorithms facilitate
the construction of network models to describe transitions
between disease states. Having gained insight into these
aberrant networks the next step in developing a networkblished by Elsevier B.V. All rights reserved.
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ent strategies for this, one involves a synthetic biology ap-
proach that aims at rewiring (by adding new interactions) of
the network using small molecules or novel synthetic modular
proteins, which we previously described [38]. This strategy ex-
ploits the modular nature of signalling proteins to change the
topology and wiring of the network by adding or depleting
interactions. A second path aims at extracting control architec-
tures and hierarchies of kinases to suggest combinations of
inhibitors to change the topology and information ﬂow within
the network. This strategy relies on the fact that network
topology is dynamic and regulated by post-translational mod-
iﬁcations such as phosphorylation. Thus, the information ﬂow
within the network can be targeted by changing the phosphor-
ylation states of key proteins.2. Directional and quantitative phosphorylation networks
Any given cell in a physiological environment receives
numerous simultaneous input cues that must be processed
and integrated to determine changes in cellular behaviour such
as migration, proliferation, apoptosis and diﬀerentiation.
Reversible protein modiﬁcations are one of the underlying
mechanisms that govern such cellular information processing.
In particular, protein phosphorylation has proven to be a pri-
mary driving force behind cellular signal propagation. Through
its ability to control protein–protein interactions, complex for-
mation, enzyme activity and protein degradation and translo-
cation, phosphorylation impacts every aspect of cellular
biology [9]. All these modes of regulation are essential for prop-
er cellular organisation and responses to input cues and we will
refer to the set of these events as a phosphorylation network. Re-
cent technical developments in mass spectrometry (MS) have
permitted the identiﬁcation and quantitation of thousands of
in vivo protein phosphorylation sites. We recently introduced
computational algorithms, NetworKIN and NetPhorest
[10,11] to further enhance the modelling of such networks based
on experimentally validated phosphorylation sites.
In combination with methods such as single-cell monitoring
by phospho-ﬂow [42,43], kinase-activity assays and conven-
tional immuno-blotting, mass-spectrometry is steadily enhanc-
ing our capability to sample the states and dynamics of cellular
signalling networks: The phospho-ﬂow technology is based on
the detection of a phosphorylation event by a speciﬁc antibody
within a single cell. Firstly, cells are labelled by antibodies rec-
ognizing speciﬁc phosphorylated proteins (for example p-ERK
or p-PKB) and cell markers (for instance CD20 or CD33). Sec-
ondly, they are sorted and measured by FACS thereby provid-
ing quantitative measurement of single-cell signalling events.
High-throughput kinase assays provide important information
for systems modelling [23,24]. Various forms of kinase assays
have been developed that use either kinase speciﬁc immuno-
puriﬁcation or speciﬁc kinase chemosensors [44,45]. The advan-
tage of these activation-based assays is that they provide a di-
rect measurement of enzyme activity, rather than an inferred
indirect activity based on alterations in phosphorylation state.
However, integration of these data are key for their interpre-
tation and utility in modelling of cellular phenotypes. There-
fore, computational tools have been developed to combine
these heterogeneous data sets and construct predictive models.
These approaches have provided insights into the complex cel-lular biology of signalling systems. We argue that these data-
driven models are important for the understanding of cellular
function under a variety of conditions such as disease, diﬀeren-
tiation, migration and apoptosis.
Mass-spectrometry is a powerful approach to the analysis of
protein networks [12–16], which can be eﬀectively used for pro-
tein quantitation, as well as the analysis of post-translational
modiﬁcations (PTM) and protein dynamics. Stable isotopes
can be introduced into proteins in cell culture (SILAC), for
quantitative or comparative purposes [14]. These reagents pro-
vide information of the relative amounts of proteins between
the network states sampled, and identify state-speciﬁc binding
partners. Another reagent type (iTRAQ, [17,18]) allows 4–8
channel multiplexed experiments in which several (currently 4–
8) diﬀerent samples can be combined; the relative amounts of
a protein can therefore be simultaneously quantiﬁed acrossmul-
tiple experimental conditions. In particular, iTRAQ allows for
the relative quantitative analysis of tissue samples, which is
important for the analysis of networks in diﬀerent cancer states
and during tumour progression. Furthermore, it allows the dy-
namic reorganization of protein networks to be monitored over
time. Perhaps the most challenging aspect of proteomics in-
volves the analysis of PTMs [14–16]. PTMs are especially impor-
tant for the dynamical changes to protein network topology,
since interactions are frequently dependent on modiﬁcations
such as phosphorylation [17,18].
Thus our ability to monitor cell signalling networks under con-
ditions relevant for disease states and their transitions, such as
gain of metastatic potential within a tumour, is rapidly grow-
ing [19].3. Cue, signal, response – from networks to cell behaviour
Constructing network models from protein–protein interac-
tion methods like LUMIER [20], yeast 2-hybrid [21] and MS
[12,13] is essential for systems level understanding of the cellu-
lar machinery. However, these networks are even more power-
ful when integrated with cellular outcome and quantitative
phenotypic data [22], which makes it possible to describe the
information processing within the system. A series of papers
from the Lauﬀenburger, Yaﬀe and White labs have combined
cue, signal and response measurements to construct models of
cellular decision processes [23–28]. The state of nodes within a
signaling network was interrogated (‘‘signal’’) in a systematic
manner using phospho-ﬂow, kinase assays, antibody-arrays
and mass-spectrometry, and correlated to cellular phenotypes
(‘‘response’’) such as apoptosis, proliferation and migration.
The signals used to perturb the system (‘‘input cues’’) were var-
ied and combined to obtain measurements of cellular re-
sponses to conﬂicting (‘‘orthogonal’’) signals. The resulting
data were subsequently subjected to data-driven modeling by
applying a combination of partial least square regression
(PLSR) and principal component analysis (PCA), for numeri-
cal modelling and data condensation, respectively. Using this
approach on large phosphorylation data sets have proven a
powerful way of deriving knowledge about critical sites and
establishing predictive models of cellular systems. As an
example, the White and Lauﬀenburger labs applied PLSR to
phospho-proteomic data and phenotypic measurements
(migration and proliferation) from cells expressing EGFR
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coeﬃcient vector indicating the importance of the identiﬁed
phosphorylation sites with respect to either migration or pro-
liferation [26,27]. By constructing a model to recapitulate the
measured data, the authors identiﬁed 9 phosphorylation events
that alone could be used to predict a cellular decision (prolif-
eration versus migration) [26,27]. PLSR has also been applied
to generate systems models for cytokine- or sepsis-induced
apoptosis and to predict a common eﬀector hypothesis for sig-
nal integration [24,25]. These models have proven useful in
predicting cellular decision processes; for example the kinase
MK2 was identiﬁed by the Yaﬀe lab to play a pro-survival role
based on its activation proﬁle in the PLSR model [28].
In addition direct sampling of a signaling network can yield
new information. For example, by performing MS quantiﬁca-
tion of a signaling network Huang et al. [16] found that ampli-
ﬁcation of c-MET, a receptor tyrosine kinase (RTK), can lead
to resistance to an inhibitor of the EGFR RTK in tumours
expressing ErbB3/EGFRvIII. Further by using phospho-spe-
ciﬁc antibody arrays or phospho-proteomics, U87 cells
expressing EGFRvIII and a lung carcinoma cell line resistant
to Geﬁtinib (Iressa) were shown to exhibit increased c-MET
activation. Combinatorial treatment with both an EGFR
inhibitor and a c-MET inhibitor had synergistic eﬀects on
growth inhibition, survival and anchorage-independent growth
[16,29]. This work shows the power of molecular networks in
deriving new drug strategies.
Technologies other than MS can be used to reveal how ther-
apeutic compounds inﬂuence cellular signaling. For instance,
to study how the signalling networks in acute myelogenous
leukemia (AML) cancer cells are correlated with clinical out-
come, the lab of Gary Nolan utilised unsupervised clustering
of phospho-ﬂow data to group samples from patients accord-
ing to their diﬀerential network proﬁles (or signatures). The
authors observed that patient response to chemotherapy was
highly correlated with the initial clustering based on the signal-
ling network state, thus indicating that the behaviour of the
individual network can be used to determine and predict pa-
tient responsiveness and choice of treatment [30].4. Network medicine – targeting networks
Above we have discussed how networks and in particular
their dynamical properties can be used to link cellular informa-
tion processing to cellular outcome and phenotype. Therefore,
we propose to exploit the knowledge of networks to investigate
mechanisms for targeting the network itself.
In a network-disease survey Barabasi and co-workers
showed that the so-called essential genes are more likely to
be hub proteins which are components of anchored and widely
expressed multi-protein complexes [31]. Furthermore, their
study showed that most disease genes are more varied in
expression patterns and with no tendency to encode such
hub proteins [31]. Similarly a network analysis identiﬁed mark-
ers not as individual genes but as subnetworks of interacting
proteins that could classify breast cancer metastasis [32]. It
was further shown that genes with known breast cancer muta-
tions reside between such subnetworks interconnecting many
diﬀerentially expressed genes.
Another issue to consider is that of ‘‘cell speciﬁcity’’, Miller-
Jensen et al. [24] showed that common eﬀector processing net-works mediate cell-speciﬁc responses to external cues. The
importance of this work and that of White and colleagues
[17,19,26] is that it is the network utilisation that seems to be
changed in diﬀerent disease states. Thus, by identifying these
subnetworks that are common across cell types but which
are utilised to diﬀerent extents, for example through changes
in phosphorylation, one can envisage they can be targeted.
These studies point to the importance of network topology
in ﬁnding markers of disease. Other studies focus on the utility
of network information in unravelling new disease genes [46].
Thus, several papers have addressed the idea of using network
information to unravel new oncogenic components, for exam-
ple by integrating various systematic datasets to construct net-
work models that identify new oncogenes in breast cancer
[33,34]. By integrating complementary genomic approaches,
Boehm and colleagues showed that the IKK-epsilon kinase is
a new breast cancer oncogene. The authors presented an ap-
proach that predicted a new mechanism for NF-kB activation
in breast cancer downstream of PI3K kinase. These studies
underline the utility of data integration and integrative dat-
abases like STRING, STICH and Phospho.ELM that incorpo-
rate the majority of large-scale datasets and cover most current
methodologies [35–37].
We envisage two types of approaches to target networks:
ﬁrstly, the network could be re-wired with small molecules or
synthetic modular proteins that introduce novel protein inter-
actions or inhibit existing ones [38–40]. Secondly, the informa-
tion ﬂow within the network can be targeted by applying
small-molecules against several nodes (for example kinases)
simultaneously. To develop this strategy, one would analyse
the topology of the measured network and correlate it to phe-
notypic markers (either molecular or macroscopic). This will
result in a better understanding of how the aberrant network
dynamics contribute to disease and will help to deﬁne multiple
protein nodes that can be targeted to rewire the network, or in-
duce the speciﬁc collapse or topology change of aberrant net-
works. We previously argued how this could be done by
utilising the modular nature of signalling networks, through
the generation of new modular synthetic proteins [38].
Given such a potential network drug (or combination of
drugs) one would want to carry out extensive sensitivity anal-
yses [41] in various cancer cell lines and with orthogonal in-
put cues [23] in order to get as realistic as possible a picture
of the response space for the drug candidate. It is essential to
point out that structural and molecular based drug develop-
ment will continue to play a central role in determining the
best leads for a given node within the network. Thus, trans-
forming medicine into a network driven endeavour goes hand
in hand with a systems level understanding of cellular infor-
mation processing.Acknowledgements: The authors thank Claus Jørgensen and Sara
Quirk for commenting on this manuscript. Funding for this work is
provided by Genome Canada through the Ontario Genomics Institute
and Cancer Research UK.
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